- Home
- CHA vs IRTC Comparison
CHA vs IRTC Comparison
Compare CHA & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHA
- IRTC
- Stock Information
- Founded
- CHA 2017
- IRTC 2006
- Country
- CHA China
- IRTC United States
- Employees
- CHA N/A
- IRTC N/A
- Industry
- CHA
- IRTC Medical/Dental Instruments
- Sector
- CHA
- IRTC Health Care
- Exchange
- CHA NYSE
- IRTC Nasdaq
- Market Cap
- CHA 5.5B
- IRTC 4.5B
- IPO Year
- CHA 2025
- IRTC 2016
- Fundamental
- Price
- CHA $28.48
- IRTC $145.74
- Analyst Decision
- CHA Strong Buy
- IRTC Strong Buy
- Analyst Count
- CHA 3
- IRTC 10
- Target Price
- CHA $40.90
- IRTC $138.60
- AVG Volume (30 Days)
- CHA 1.2M
- IRTC 457.7K
- Earning Date
- CHA 05-30-2025
- IRTC 07-31-2025
- Dividend Yield
- CHA N/A
- IRTC N/A
- EPS Growth
- CHA 97.45
- IRTC N/A
- EPS
- CHA 2.05
- IRTC N/A
- Revenue
- CHA $1,831,698,754.00
- IRTC $618,587,000.00
- Revenue This Year
- CHA $26.02
- IRTC $19.91
- Revenue Next Year
- CHA $25.07
- IRTC $16.81
- P/E Ratio
- CHA $13.91
- IRTC N/A
- Revenue Growth
- CHA 97.51
- IRTC 20.54
- 52 Week Low
- CHA $27.21
- IRTC $55.92
- 52 Week High
- CHA $41.80
- IRTC $150.00
- Technical
- Relative Strength Index (RSI)
- CHA N/A
- IRTC 63.44
- Support Level
- CHA N/A
- IRTC $141.19
- Resistance Level
- CHA N/A
- IRTC $146.90
- Average True Range (ATR)
- CHA 0.00
- IRTC 3.50
- MACD
- CHA 0.00
- IRTC -1.09
- Stochastic Oscillator
- CHA 0.00
- IRTC 63.96
About CHA CHAGEE HOLDINGS LTD SPON ADS EACH R SPON ADS EACH REP 1 CL A
Chagee Holdings Ltd is a premium tea drinks brand. It is engaged in the sales of freshly-made tea drinks, related raw materials, packaging, teahouse equipment and other supplies in China.
About IRTC iRhythm Technologies Inc.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.